Aclarion's Nociscan AI Advances Understanding of Modic Changes in Chronic Low Back Pain
TL;DR
Aclarion's Nociscan solution provides critical insights into the location of a patient's low back pain, giving clinicians a competitive advantage in optimizing treatment strategies.
The Nociscan solution uses MR Spectroscopy (MRS) to measure intradiscal propionic acid (PA) levels adjacent to vertebral endplates, clarifying Modic changes (MC) etiology and informing better treatment decisions.
Aclarion's innovative research and Nociscan technology aim to provide personalized treatment plans for chronic low back pain patients, ultimately improving patient outcomes and quality of life.
The results challenge the notion that the disc environment is sterile, providing an interesting and educational insight into the causes of chronic low back pain.
Found this article helpful?
Share it with your network and spread the knowledge!
Aclarion, Inc.'s Nociscan AI solution has played a crucial role in advancing the understanding of Modic changes (MC) in chronic low back pain (cLBP) patients, according to research presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024 in Milan, Italy. The study, involving 88 patients with low back pain lasting more than three months, utilized Nociscan's magnetic resonance spectroscopy (MRS) technology to measure intradiscal propionic acid (PA) levels adjacent to vertebral endplates with MC.
Dr. Aaron Fields from the REACH Center at UCSF, who led the study, emphasized the importance of clarifying the biopsychosocial mechanisms of chronic low back pain for developing personalized and effective care. The research findings challenge the long-held belief that the disc environment is sterile and suggest that PA levels could be instrumental in understanding why some patients with MC improve or respond to treatment while others do not.
Aclarion's Nociscan solution, the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine, objectively quantifies chemical biomarkers associated with disc pain. This technology provides critical insights into the location of a patient's low back pain when used in conjunction with other diagnostic tools.
The study's implications are significant for the 266 million people globally suffering from spinal degeneration and low back pain. By utilizing Nociscan to measure PA as a way to stratify patients with Modic changes, researchers are paving the way for potential personalized treatment approaches. Future research may explore treating cLBP patients with high levels of PA with antibiotics as a first line of treatment to evaluate whether this improves clinical outcomes.
Ryan Bond, Chief Strategy Officer at Aclarion, highlighted the company's focus on providing physicians with new noninvasive information to help make better decisions about patient care. The innovative use of Nociscan technology to identify biomarkers opens up possibilities for developing personalized treatment plans aimed at improving patient outcomes.
This research represents a significant step forward in understanding the complex nature of chronic low back pain and the role of Modic changes. By challenging existing notions and providing new insights into potential bacterial involvement in disc pain, Aclarion's Nociscan technology is contributing to the advancement of diagnostic and treatment strategies for cLBP patients. As further developments emerge from this line of research, it could lead to more targeted and effective treatments for millions of people suffering from chronic low back pain worldwide.
Curated from NewMediaWire
